1932

Abstract

Deleterious germline variants are now recognized as common drivers of hematopoietic malignancies (HMs) and bone marrow failure syndromes. With the increasing use of personalized medicine and the application of tumor-based profiling via next-generation sequencing, diagnosis of HM predisposition occurs with increasing frequency. Although deleterious germline variants can be readily identified by comprehensive clinical testing, numerous barriers exist for many clinicians. Observations regarding particular germline predisposition disorders challenge widely held assumptions about these conditions. Here, we review approaches to germline genetic testing, highlighting key points in a typical patient's course that present challenges for testing and interpreting results. Increasing awareness by health care providers of these conditions and improvements in testing platforms are crucial for enabling a proactive approach to tailoring a suitable treatment plan and surveillance program for the patient and their family members.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-cancerbio-062822-112257
2024-06-12
2025-02-08
Loading full text...

Full text loading...

/deliver/fulltext/cancerbio/8/1/annurev-cancerbio-062822-112257.html?itemId=/content/journals/10.1146/annurev-cancerbio-062822-112257&mimeType=html&fmt=ahah

Literature Cited

  1. Ababou M. 2021.. Bloom syndrome and the underlying causes of genetic instability. . Mol. Genet. Metab. 133::3548
    [Crossref] [Google Scholar]
  2. Abel HJ, Oetjen KA, Miller CA, Ramakrishnan SM, Day RB, et al. 2023.. Genomic landscape of TP53-mutated myeloid malignancies. . Blood Adv. 7::458698
    [Crossref] [Google Scholar]
  3. Ahn IE, Brown JR. 2021.. Targeting Bruton's tyrosine kinase in CLL. . Front. Immunol. 12::687458
    [Crossref] [Google Scholar]
  4. Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. 2019.. Mechanisms of PTEN loss in cancer: It's all about diversity. . Semin. Cancer Biol. 59::6679
    [Crossref] [Google Scholar]
  5. Ames K, Kaur I, Shi Y, Tong MM, Sinclair T, et al. 2023.. PI3-kinase deletion promotes myelodysplasia by dysregulating autophagy in hematopoietic stem cells. . Sci. Adv. 9::eade8222
    [Crossref] [Google Scholar]
  6. Andrades A, Peinado P, Alvarez-Perez JC, Sanjuan-Hidalgo J, García DJ, et al. 2023.. SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities. . Mol. Cancer 22::39
    [Crossref] [Google Scholar]
  7. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, et al. 2022.. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. . Blood 140::120028
    [Crossref] [Google Scholar]
  8. Armes H, Bewicke-Copley F, Rio-Machin A, Di Bella D, Philippe C, et al. 2022.. Germline ERCC excision repair 6 like 2 (ERCC6L2) mutations lead to impaired erythropoiesis and reshaping of the bone marrow microenvironment. . Br. J. Haematol. 199::75464
    [Crossref] [Google Scholar]
  9. Asada S, Kitamura T. 2021.. Clonal hematopoiesis and associated diseases: a review of recent findings. . Cancer Sci. 112::396271
    [Crossref] [Google Scholar]
  10. Asnagli H, Minet N, Pfeiffer C, Hoeben E, Lane R, et al. 2023.. CTP synthase 1 is a novel therapeutic target in lymphoma. . Hemasphere 7::e864
    [Crossref] [Google Scholar]
  11. Baccelli F, Leardini D, Cerasi S, Messelodi D, Bertuccio SN, Masetti R. 2023.. ERCC6L2-related disease: a novel entity of bone marrow failure disorder with high risk of clonal evolution. . Ann. Hematol. 102::699705
    [Crossref] [Google Scholar]
  12. Batista LFZ, Dokal I, Parker R. 2022.. Telomere biology disorders: time for moving towards the clinic?. Trends Mol. Med. 28::88291
    [Crossref] [Google Scholar]
  13. Beghini A, Leuzzi L, Abazari N, Bossi LE, Guido V, et al. 2022.. A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms. . Hematol. Oncol. 40::110912
    [Crossref] [Google Scholar]
  14. Belizaire R, Wong WJ, Robinette ML, Ebert BL. 2023.. Clonal haematopoiesis and dysregulation of the immune system. . Nat. Rev. Immunol. 23::595610
    [Crossref] [Google Scholar]
  15. Bi L, Ma T, Li X, Wei L, Liu Z, et al. 2021.. New progress in the study of germline susceptibility genes of myeloid neoplasms. . Oncol. Lett. 21::317
    [Crossref] [Google Scholar]
  16. Bonfim C. 2020.. Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes. . Hematol. Am. Soc. Hematol. Educ. Program 2020::10714
    [Crossref] [Google Scholar]
  17. Byrjalsen A, Brainin AE, Lund TK, Andersen MK, Jelsig AM. 2023.. Size matters in telomere biology disorders – expanding phenotypic spectrum in patients with long or short telomeres. . Hered. Cancer Clin. Pract 21::7
    [Crossref] [Google Scholar]
  18. Calvo KR, Hickstein DD. 2023.. The spectrum of GATA2 deficiency syndrome. . Blood 141::152432
    [Crossref] [Google Scholar]
  19. Christofides A, Katopodi XL, Cao C, Karagkouni D, Aliazis K, et al. 2023.. SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses. . Nat. Immunol. 24::5568
    [Crossref] [Google Scholar]
  20. Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, et al. 2016.. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. . Cancer 122::30411
    [Crossref] [Google Scholar]
  21. Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, et al. 2015.. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. . Blood 126::248490
    [Crossref] [Google Scholar]
  22. Chyra Kufova Z, Sevcikova T, Januska J, Vojta P, Boday A, et al. 2018.. Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing. . J. Clin. Pathol. 71::68794
    [Crossref] [Google Scholar]
  23. Claus C, Ferrara-Koller C, Klein C. 2023.. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. . MAbs 15::2167189
    [Crossref] [Google Scholar]
  24. Davidsson J, Puschmann A, Tedgård U, Bryder D, Nilsson L, Cammenga J. 2018.. SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies. . Leukemia 32::110615
    [Crossref] [Google Scholar]
  25. DeRoin L, Cavalcante de Andrade Silva M, Petras K, Arndt K, Phillips N, et al. 2022.. Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. . Hum. Mutat. 43::95062
    [Crossref] [Google Scholar]
  26. Dhanraj S, Matveev A, Li H, Lauhasurayotin S, Jardine L, et al. 2017.. Biallelic mutations in DNAJC21 cause Shwachman-Diamond syndrome. . Blood 129::155762
    [Crossref] [Google Scholar]
  27. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, et al. 2022.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. . Blood 140::134577
    [Crossref] [Google Scholar]
  28. Doi T, Okada S. 2020.. [ Lymphoproliferative disorders and inborn errors of immunity. ]. Rinsho Ketsueki 61::136572
    [Google Scholar]
  29. Douglas SPM, Siipola P, Kovanen PE, Pyörälä M, Kakko S, et al. 2019.. ERCC6L2 defines a novel entity within inherited acute myeloid leukemia. . Blood 133::272428
    [Crossref] [Google Scholar]
  30. Driessen GJ, Ijspeert H, Weemaes CM, Haraldsson Á, Trip M, et al. 2013.. Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. . J. Allergy Clin. Immunol. 131::136775.e9
    [Crossref] [Google Scholar]
  31. Fallahi M, Jamee M, Enayat J, Abdollahimajd F, Mesdaghi M, et al. 2022.. Novel PGM3 mutation in two siblings with combined immunodeficiency and childhood bullous pemphigoid: a case report and review of the literature. . Allergy Asthma Clin. Immunol. 18::111
    [Crossref] [Google Scholar]
  32. Fang CB, Wu HT, Zhang ML, Liu J, Zhang GJ. 2020.. Fanconi anemia pathway: mechanisms of breast cancer predisposition development and potential therapeutic targets. . Front. Cell Dev. Biol. 8::160
    [Crossref] [Google Scholar]
  33. Faoro C, Ataide SF. 2021.. Noncanonical functions and cellular dynamics of the mammalian signal recognition particle components. . Front. Mol. Biosci. 8::679584
    [Crossref] [Google Scholar]
  34. Feurstein S. 2023.. Emerging bone marrow failure syndromes- new pieces to an unsolved puzzle. . Front. Oncol. 13::1128533
    [Crossref] [Google Scholar]
  35. Feurstein S, Godley LA. 2017.. Germline ETV6 mutations and predisposition to hematological malignancies. . Int. J. Hematol. 106::18995
    [Crossref] [Google Scholar]
  36. Feurstein S, Hahn CN, Mehta N, Godley LA. 2022a.. A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias. . Genet. Med. 24::93154
    [Crossref] [Google Scholar]
  37. Feurstein S, Luo X, Shah M, Walker T, Mehta N, et al. 2022b.. Revision of RUNX1 variant curation rules. . Blood Adv. 6::472630
    [Crossref] [Google Scholar]
  38. Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, et al. 2022.. The CD70-CD27 axis in oncology: the new kids on the block. . J. Exp. Clin. Cancer Res. 41::12
    [Crossref] [Google Scholar]
  39. Fouad FM, Eid JI. 2023.. PAX5 fusion genes in acute lymphoblastic leukemia: A literature review. . Medicine 102::e33836
    [Crossref] [Google Scholar]
  40. Geng J, Zhao M, Li Q. 2022.. Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review. . Hematology 27::104145
    [Crossref] [Google Scholar]
  41. George B, Kantarjian H, Baran N, Krocker JD, Rios A. 2021.. TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation. . Int. J. Mol. Sci. 22::10782
    [Crossref] [Google Scholar]
  42. Godley LA. 2023.. Prioritization of patients for germline testing based on tumor profiling of hematopoietic malignancies. . Front. Oncol. 13::1084736
    [Crossref] [Google Scholar]
  43. Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, et al. 2022.. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. . J. Natl. Compr. Cancer Netw. 20::10617
    [Crossref] [Google Scholar]
  44. Grill S, Nandakumar J. 2021.. Molecular mechanisms of telomere biology disorders. . J. Biol. Chem. 296::100064
    [Crossref] [Google Scholar]
  45. Guastafierro V, Ubezio M, Manes N, Milanesi C, Della Porta M, Bonometti A. 2023.. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature. . Leuk. Lymphoma 64::156673
    [Crossref] [Google Scholar]
  46. Hakkarainen M, Kaaja I, Douglas SPM, Vulliamy T, Dokal I, et al. 2023.. The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia. . Blood 141::285366
    [Google Scholar]
  47. Hamilton KV, Maese L, Marron JM, Pulsipher MA, Porter CC, Nichols KE. 2019.. Stopping leukemia in its tracks: Should preemptive hematopoietic stem-cell transplantation be offered to patients at increased genetic risk for acute myeloid leukemia?. J. Clin. Oncol. 37::2098104
    [Crossref] [Google Scholar]
  48. Hayashi Y, Harada Y, Harada H. 2022.. Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective. . Leukemia 36::120314
    [Crossref] [Google Scholar]
  49. Hayashi Y, Harada Y, Huang G, Harada H. 2017.. Myeloid neoplasms with germ line RUNX1 mutation. . Int. J. Hematol. 106::18388
    [Crossref] [Google Scholar]
  50. Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, et al. 2022.. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. . Haematologica 107::17886
    [Crossref] [Google Scholar]
  51. Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, et al. 2023a.. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. . Blood Adv. 7::6092107
    [Crossref] [Google Scholar]
  52. Homan CC, Scott HS, Brown AL. 2023b.. Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26. . Blood 141::153343
    [Crossref] [Google Scholar]
  53. Homan CC, Venugopal P, Arts P, Shahrin NH, Feurstein S, et al. 2021.. GATA2 deficiency syndrome: a decade of discovery. . Hum. Mutat. 42::1399421
    [Crossref] [Google Scholar]
  54. Hsu AP. 2023.. Not too little, not too much: the impact of mutation types in Wiskott-Aldrich syndrome and RAC2 patients. . Clin. Exp. Immunol. 212::13746
    [Crossref] [Google Scholar]
  55. Ioannou A, Fontana M, Gillmore JD. 2023.. RNA targeting and gene editing strategies for transthyretin amyloidosis. . BioDrugs 37::12742
    [Crossref] [Google Scholar]
  56. Jeraj N, Hegele RA, Berberich AJ. 2021.. Apolipoprotein genetic variants and hereditary amyloidosis. . Curr. Opin. Lipidol. 32::13240
    [Crossref] [Google Scholar]
  57. Jia Z, Gu Z. 2022.. PAX5 alterations in B-cell acute lymphoblastic leukemia. . Front. Oncol. 12::1023606
    [Crossref] [Google Scholar]
  58. Jiang Y, Zhang J, Zhang C, Hong L, Jiang Y, et al. 2020.. The role of cystatin C as a proteasome inhibitor in multiple myeloma. . Hematology 25::45763
    [Crossref] [Google Scholar]
  59. Kakadia PM, Van de Water N, Browett PJ, Bohlander SK. 2018.. Efficient identification of somatic mutations in acute myeloid leukaemia using whole exome sequencing of fingernail derived DNA as germline control. . Sci. Rep. 8::13751
    [Crossref] [Google Scholar]
  60. Kam MLW, Nguyen TTT, Ngeow JYY. 2021.. Telomere biology disorders. . NPJ Genomic Med. 6::36
    [Crossref] [Google Scholar]
  61. Kawashima N, Oyarbide U, Cipolli M, Bezzerri V, Corey SJ. 2023.. Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants. . Haematologica 108::2594605
    [Crossref] [Google Scholar]
  62. Kermasson L, Churikov D, Awad A, Smoom R, Lainey E, et al. 2022.. Inherited human Apollo deficiency causes severe bone marrow failure and developmental defects. . Blood 139::242740
    [Crossref] [Google Scholar]
  63. Khan I, Gartel AL. 2022.. The antagonistic duality of NPM1 mutations in AML. . Blood Adv. 6::402830
    [Crossref] [Google Scholar]
  64. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, et al. 2022.. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. . Leukemia 36::170319
    [Crossref] [Google Scholar]
  65. Kim K, Ong F, Sasaki K. 2023.. Current understanding of DDX41 mutations in myeloid neoplasms. . Cancers 15::344
    [Crossref] [Google Scholar]
  66. Kim R, Bergugnat H, Larcher L, Duchmann M, Passet M, et al. 2023.. Adult low-hypodiploid acute lymphoblastic leukemia emerges from preleukemic TP53-mutant clonal hematopoiesis. . Blood Cancer Discov. 4::13449
    [Crossref] [Google Scholar]
  67. Kraft IL, Godley LA. 2020.. Identifying potential germline variants from sequencing hematopoietic malignancies. . Blood 136::2498506
    [Crossref] [Google Scholar]
  68. Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, et al. 2022.. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. . J. Clin. Oncol. 40::152941
    [Crossref] [Google Scholar]
  69. López-Nevado M, González-Granado LI, Ruiz-García R, Pleguezuelo D, Cabrera-Marante O, et al. 2021.. Primary immune regulatory disorders with an autoimmune lymphoproliferative syndrome-like phenotype: immunologic evaluation, early diagnosis and management. . Front. Immunol. 12::671755
    [Crossref] [Google Scholar]
  70. Lovatel VL, Bueno AP, de Kós EAA, Meyer LGC, Ferreira GM, et al. 2023.. A novel constitutional t(3;8)(p26;q21) and ANKRD26 and SRP72 variants in a child with myelodysplastic neoplasm: clinical implications. . J. Clin. Med. 12::3171
    [Crossref] [Google Scholar]
  71. Lozano Chinga MM, Bertuch AA, Afify Z, Dollerschell K, Hsu JI, et al. 2023.. Expanded phenotypic and hematologic abnormalities beyond bone marrow failure in MECOM-associated syndromes. . Am. J. Med. Genet. A 191::182635
    [Crossref] [Google Scholar]
  72. Luo X, Feurstein S, Mohan S, Porter CC, Jackson SA, et al. 2019.. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. . Blood Adv. 3::296279
    [Crossref] [Google Scholar]
  73. Luong TT, Bernstein KA. 2021.. Role and regulation of the RECQL4 family during genomic integrity maintenance. . Genes 12::1919
    [Crossref] [Google Scholar]
  74. Makishima H, Bowman TV, Godley LA. 2023a.. DDX41-associated susceptibility to myeloid neoplasms. . Blood 141::154452
    [Crossref] [Google Scholar]
  75. Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, et al. 2023b.. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. . Blood 141::53449
    [Crossref] [Google Scholar]
  76. Mastrolia I, Foppiani EM, Murgia A, Candini O, Samarelli AV, et al. 2019.. Challenges in clinical development of mesenchymal stromal/stem cells: concise review. . Stem Cells Transl. Med. 8::113548
    [Crossref] [Google Scholar]
  77. McCormick BJ, Chirila RM. 2023.. ANKRD26 gene variant of uncertain significance in a patient with acute myeloid leukemia. . Cureus 15::e36152
    [Google Scholar]
  78. Moreno OM, Paredes AC, Suarez-Obando F, Rojas A. 2021.. An update on Fanconi anemia: clinical, cytogenetic and molecular approaches (review). . Biomed. Rep. 15::74
    [Crossref] [Google Scholar]
  79. Narumi S. 2022.. Discovery of MIRAGE syndrome. . Pediatr. Int. 64::e15283
    [Crossref] [Google Scholar]
  80. Nasri Nasrabadi P, Martin D, Gharib E, Robichaud GA. 2022.. The pleiotropy of PAX5 gene products and function. . Int. J. Mol. Sci. 23::10095
    [Crossref] [Google Scholar]
  81. O'Connor TE, Shaw R, Madero-Marroquin R, Roloff GW. 2023.. Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy. . Front. Oncol. 13::1180439
    [Crossref] [Google Scholar]
  82. Ohguchi Y, Ohguchi H. 2023.. DIS3: the enigmatic gene in multiple myeloma. . Int. J. Mol. Sci. 24::4079
    [Crossref] [Google Scholar]
  83. Otahalova B, Volkova Z, Soukupova J, Kleiblova P, Janatova M, et al. 2023.. Importance of germline and somatic alterations in human MRE11, RAD50, and NBN genes coding for MRN complex. . Int. J. Mol. Sci. 24::5612
    [Crossref] [Google Scholar]
  84. Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, et al. 2008.. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. . Blood 112::463945
    [Crossref] [Google Scholar]
  85. Palles C, West HD, Chew E, Galavotti S, Flensburg C, et al. 2022.. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. . Am. J. Hum. Genet. 109::95360
    [Crossref] [Google Scholar]
  86. Palmisani E, Miano M, Grossi A, Lanciotti M, Lupia M, et al. 2023.. Autoimmune lymphoproliferative syndrome (ALPS) disease and ALPS phenotype: Are they two distinct entities?. Hemasphere 7::e845
    [Crossref] [Google Scholar]
  87. Passamonti F, Mora B. 2023.. Myelofibrosis. . Blood 141::195470
    [Crossref] [Google Scholar]
  88. Peduto C, Zanobio M, Nigro V, Perrotta S, Piluso G, Santoro C. 2023.. Neurofibromatosis type 1: pediatric aspects and review of genotype-phenotype correlations. . Cancers 15::1217
    [Crossref] [Google Scholar]
  89. Petley E, Yule A, Alexander S, Ojha S, Whitehouse WP. 2022.. The natural history of ataxia-telangiectasia (A-T): a systematic review. . PLOS ONE 17::e0264177
    [Crossref] [Google Scholar]
  90. Potrč M, Volk M, de Rosa M, Pižem J, Teran N, et al. 2021.. Clinical and histopathological features of gelsolin amyloidosis associated with a novel GSN variant p.Glu580Lys. . Int. J. Mol. Sci. 22::1084
    [Crossref] [Google Scholar]
  91. Rajput RV, Arnold DE. 2023.. GATA2 deficiency: predisposition to myeloid malignancy and hematopoietic cell transplantation. . Curr. Hematol. Malig. Rep. 18::8997
    [Crossref] [Google Scholar]
  92. Raskind WH, Chen DH, Bird T. 1993.. SAMD9L ataxia-pancytopenia syndrome. . In GeneReviews®, ed. MP Adam, GM Mirzaa, RA Pagon, SE Wallace, LJH Bean, et al . Seattle:: Univ. Wash.
    [Google Scholar]
  93. Reed F, Larsuel ST, Mayday MY, Scanlon V, Krause DS. 2021.. MRTFA: a critical protein in normal and malignant hematopoiesis and beyond. . J. Biol. Chem. 296::100543
    [Crossref] [Google Scholar]
  94. Reilly CR, Shimamura A. 2023.. Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances. . Blood 141::151323
    [Crossref] [Google Scholar]
  95. Richards S, Aziz N, Bale S, Bick D, Das S, et al. 2015.. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. . Genet. Med. 17::40524
    [Crossref] [Google Scholar]
  96. Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, et al. 2016.. Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy. . Biol. Blood Marrow Transplant. 22::21003
    [Crossref] [Google Scholar]
  97. Roloff GW, Godley LA, Drazer MW. 2021.. Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. . Genet. Med. 23::21114
    [Crossref] [Google Scholar]
  98. Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS. 2006.. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. . Blood 108::63844
    [Crossref] [Google Scholar]
  99. Rudelius M, Weinberg OK, Niemeyer CM, Shimamura A, Calvo KR. 2023.. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia. . Virchow's Arch. 482::11330
    [Crossref] [Google Scholar]
  100. Sadeghi P, Esslami GG, Rokni-Zadeh H, Changi-Ashtiani M, Mohsenipour R. 2022.. Familial hemophagocytic lymphohistiocytosis secondary to UNC13D mutation: a report of two cases. . BMC Pediatr. 22::667
    [Crossref] [Google Scholar]
  101. Sahoo SS, Kozyra EJ, Wlodarski MW. 2020.. Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes. . Best Pract. Res. Clin. Haematol. 33::101197
    [Crossref] [Google Scholar]
  102. Saiki R, Ogawa S. 2023.. Adult low-hypodiploid acute lymphoblastic leukemia evolves from TP53-mutated clonal hematopoiesis. . Blood Cancer Discov. 4::1025
    [Crossref] [Google Scholar]
  103. Santiago M, Liquori A, Such E, Zúñiga Á, Cervera J. 2023.. The clinical spectrum, diagnosis, and management of GATA2 deficiency. . Cancers 15::1590
    [Crossref] [Google Scholar]
  104. Savage SA, Niewisch MR. 1993.. Dyskeratosis congenita and related telomere biology disorders. . In GeneReviews®, ed. MP Adam, GM Mirzaa, RA Pagon, SE Wallace, LJH Bean, et al . Seattle:: Univ. Wash.
    [Google Scholar]
  105. Saygin C, Roloff G, Hahn CN, Chhetri R, Gill S, et al. 2023.. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. . Blood Adv. 7::54954
    [Crossref] [Google Scholar]
  106. Schlegelberger B, Mecucci C, Wlodarski M. 2021.. Review of guidelines for the identification and clinical care of patients with genetic predisposition for hematological malignancies. . Fam. Cancer 20::295303
    [Crossref] [Google Scholar]
  107. Schmidt L, Heyes E, Grebien F. 2020.. Gain-of-function effects of N-terminal CEBPA mutations in acute myeloid leukemia. . Bioessays 42::e1900178
    [Crossref] [Google Scholar]
  108. Shabanova I, Cohen E, Cada M, Vincent A, Cohn RD, Dror Y. 2018.. ERCC6L2-associated inherited bone marrow failure syndrome. . Mol. Genet. Genomic Med. 6::46368
    [Crossref] [Google Scholar]
  109. Shadman M. 2023.. Diagnosis and treatment of chronic lymphocytic leukemia: a review. . JAMA 329::91832
    [Crossref] [Google Scholar]
  110. Spinetti E, Delre P, Saviano M, Siliqi D, Lattanzi G, Mangiatordi GF. 2022.. A comparative molecular dynamics study of selected point mutations in the Shwachman-Bodian-Diamond syndrome protein SBDS. . Int. J. Mol. Sci. 23::7938
    [Crossref] [Google Scholar]
  111. Srinivasan S, Ramanathan S, Kumar S, Peyam S, Radhakrishnan V. 2023.. Prevalence and prognostic significance of IKZF1 deletion in paediatric acute lymphoblastic leukemia: a systematic review and meta-analysis. . Ann. Hematol. 102::216579
    [Crossref] [Google Scholar]
  112. Stolarova L, Kleiblova P, Janatova M, Soukupova J, Zemankova P, et al. 2020.. CHEK2 germline variants in cancer predisposition: stalemate rather than checkmate. . Cells 9::2675
    [Crossref] [Google Scholar]
  113. Stubbins RJ, Asom AS, Wang P, Lager AM, Gary A, Godley LA. 2024.. Germline loss of function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic malignancies. . Haematologica 109::35156
    [Google Scholar]
  114. Stubbins RJ, Korotev S, Godley LA. 2022.. Germline CHEK2 and ATM variants in myeloid and other hematopoietic malignancies. . Curr. Hematol. Malig. Rep. 17::94104
    [Crossref] [Google Scholar]
  115. Sullivan MJ, Palmer EL, Botero JP. 2022.. ANKRD26-related thrombocytopenia and predisposition to myeloid neoplasms. . Curr. Hematol. Malig. Rep. 17::10512
    [Crossref] [Google Scholar]
  116. Surapally S, Tenen DG, Pulikkan JA. 2021.. Emerging therapies for inv(16) AML. . Blood 137::257984
    [Crossref] [Google Scholar]
  117. Szuber N, Tefferi A. 2021.. Current management of chronic neutrophilic leukemia. . Curr. Treat. Options Oncol. 22::59
    [Crossref] [Google Scholar]
  118. Tanase-Nakao K, Olson TS, Narumi S. 1993.. MIRAGE syndrome. . In GeneReviews®, ed. MP Adam, GM Mirzaa, RA Pagon, SE Wallace, LJH Bean, et al . Seattle:: Univ. Wash.
    [Google Scholar]
  119. Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H. 2021.. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. . Pharmacol. Ther. 219::107709
    [Crossref] [Google Scholar]
  120. Tefferi A. 2021.. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. . Am. J. Hematol. 96::14562
    [Crossref] [Google Scholar]
  121. Tefferi A, Barbui T. 2020.. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. . Am. J. Hematol. 95::1599613
    [Crossref] [Google Scholar]
  122. Trottier AM, Godley LA. 2021.. Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. . Br. J. Haematol. 194::66376
    [Crossref] [Google Scholar]
  123. Tummala H, Walne AJ, Williams M, Bockett N, Collopy L, et al. 2016.. DNAJC21 mutations link a cancer-prone bone marrow failure syndrome to corruption in 60S ribosome subunit maturation. . Am. J. Hum. Genet. 99::11524
    [Crossref] [Google Scholar]
  124. Vyas H, Alcheikh A, Lowe G, Stevenson WS, Morgan NV, Rabbolini DJ. 2022.. Prevalence and natural history of variants in the ANKRD26 gene: a short review and update of reported cases. . Platelets 33::110712
    [Crossref] [Google Scholar]
  125. Wagener R, Elitzur S, Brozou T, Borkhardt A. 2023.. Functional damaging germline variants in ETV6, IKZF1, PAX5 and RUNX1 predisposing to B-cell precursor acute lymphoblastic leukemia. . Eur. J. Med. Genet. 66::104725
    [Crossref] [Google Scholar]
  126. Wang Q-S, Wei S-R, Xiao H-L. 2020.. RBBP6 induces non-small cell lung cancer cell proliferation and high expression is associated with poor prognosis. . Oncol. Lett. 19::2895901
    [Google Scholar]
  127. Warren JT, Di Paola J. 2022.. Genetics of inherited thrombocytopenias. . Blood 139::326477
    [Crossref] [Google Scholar]
  128. Wlodarski MW, Collin M, Horwitz MS. 2017.. GATA2 deficiency and related myeloid neoplasms. . Semin. Hematol. 54::8186
    [Crossref] [Google Scholar]
  129. Wu D, Luo X, Feurstein S, Kesserwan C, Mohan S, et al. 2020.. How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies. . Haematologica 105::87087
    [Crossref] [Google Scholar]
  130. Xiao H, Shi J, Luo Y, Tan Y, He J, et al. 2011.. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. . Blood 117::525760
    [Crossref] [Google Scholar]
  131. Yoshida M, Tanase-Nakao K, Shima H, Shirai R, Yoshida K, et al. 2020.. Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7. . Br. J. Haematol. 191::83543
    [Crossref] [Google Scholar]
  132. Yuan J, He R, Alkhateeb HB. 2023.. Sporadic and familial acute myeloid leukemia with CEBPA mutations. . Curr. Hematol. Malig. Rep. 18::12129
    [Crossref] [Google Scholar]
  133. Zhang L, Cao Y, Dai X, Zhang X. 2022.. Deciphering the role of DOCK8 in tumorigenesis by regulating immunity and the application of nanotechnology in DOCK8 deficiency therapy. . Front. Pharmacol. 13::1065029
    [Crossref] [Google Scholar]
  134. Zhang S, Liu M, Yao Y, Yu B, Liu H. 2021.. Targeting LSD1 for acute myeloid leukemia (AML) treatment. . Pharmacol. Res. 164::105335
    [Crossref] [Google Scholar]
  135. Zhao P, Hu Y, Sun D, Meng Q, Zhang L, et al. 2022.. A novel CARD11 germline mutation in a Chinese patient of B cell expansion with NF-κB and T cell anergy (BENTA) and literature review. . Front. Immunol. 13::943027
    [Crossref] [Google Scholar]
/content/journals/10.1146/annurev-cancerbio-062822-112257
Loading
/content/journals/10.1146/annurev-cancerbio-062822-112257
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error